Fig. 7: Blockade of VRK2 enhances the therapeutic effect of Anti-PD-1mAb in a mouse model of HCC. | Nature Communications

Fig. 7: Blockade of VRK2 enhances the therapeutic effect of Anti-PD-1mAb in a mouse model of HCC.

From: VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization

Fig. 7

a Schematic representation of the DEN/CCL4 HCC development model induced in WT C57BL/6J mice (n = 5 mice in each group) and drug delivery strategy. b DEN/CCL4 model in C57BL/6J mice with representative images are presented that show the MRI images, liver with tumor images and H&E, Oil Red, Ki67, PD-L1, and CD8 staining of isolated liver tissues. Gross image Scale bar: 1 cm, IHC image Scale bar: 200 μm. c Schematic representation of the HTVi HCC development model (Myc/sgTp53) induced in WT C57BL/6J mice (n = 5 mice in each group) and drug delivery strategy. Gross image Scale bar: 1 cm, IHC image Scale bar: 200 μm. d HTVi model in C57BL/6J mice with representative images are presented that show the bioluminescence, liver with tumor images and H&E, Oil Red, Ki67, PD-L1, and CD8 staining of isolated liver tissues. e, f Flow cytometry analysis of CD3+, CD8+, CD69+CD8+, IFN-γ+CD8+, and PD-1+CD8+ in TILs from DEN/CCL4 model or HTVi model tumors tissues in C57BL/6J mice (n = 5 mice in each group). e, f P values were calculated using a student’s unpaired t-test (two-tailed). Data were presented as the mean ± SD. Source data are provided as a Source Data file.

Back to article page